SARS-CoV-2 IgG Quantitative ELISA Kit (DEIASL019Q)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Serum, plasma
Species Reactivity
Intended Use
This kit is used for the quantitative detection of novel coronavirus IgG antibodies in human serum or plasma in vitro.
This kit is stored at 2 ~ 8 °C, the validity period is 6 months.
Avoid freezing and use within the validity period.
Detection Range
The detection range of this kit is 39.506-200 ng/mL.
General Description
The new coronavirus belongs to the beta coronavirus of the genus β, which has an envelope, the particles are round or oval, often polymorphic, and the diameter is 60-140 nm. Its genetic characteristics are significantly different from SARSr-CoV and MERSr-CoV. Current research shows that it has more than 85% homology with bat SARS-like coronavirus (bat-SL- CoVZC45). In vitro isolation and culture, 2019-nCoV can be found in human respiratory epithelial cells in about 96 hours, while it takes about 6 days to isolate and culture in Vero E6 and Huh-7 cell lines. Based on current epidemiological investigations, the incubation period is generally 7 days, with a maximum of 14 days. Main symptoms are fever, fatigue, and dry cough. A few patients have symptoms such as nasal congestion, runny nose, and diarrhea. In severe cases, dyspnea occurs more than a week later. In severe cases, acute respiratory distress syndrome, septic shock, difficult to correct metabolic acidosis, and coagulation dysfunction develop rapidly. It is worth nothing that in the course of severe and critically ill patients, there may be moderate to low fever, even without obvious fever. Some patients showed only low fever, mild fatigue, and no pneumonia and recovered after 1 week. In the early stages of the disease, the total number of white blood cells in the peripheral blood was normal or decreased, the lymphocyte count decreased, and some patients had increased liver enzymes, muscle enzymes, and myoglobin. Most patients have elevated C- reactive protein (CRP) and erythrocyte sedimentation rate and normal procalcitonin. In severe cases, D-dimer increases and peripheral blood lymphocytes progressively decrease. New coronavirus nucleic acids can be detected in throat swabs, sputum, lower respiratory tract secretions, and blood. Serum antibody testing helps confirm the infection status of a case.


Have you cited DEIASL019Q in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Liver transplantation in a patient after COVID-19-Rapid loss of antibodies and prolonged viral RNA shedding


Authors: Niess, Hanno; Borner, Nikolaus; Muenchhoff, Maximilian; Khatamzas, Elham; Stangl, Manfred; Graf, Alex; Girl, Philipp; Georgi, Enrico; Koliogiannis, Dionysios; Denk, Gerald; Irlbeck, Michael; Werner, Jens; Guba, Markus

To date, little is known about the duration and effectiveness of immunity as well as possible adverse late effects after an infection with SARS-CoV-2. Thus it is unclear, when and if liver transplantation can be safely offered to patients who suffered from COVID-19. Here, we report on a successful liver transplantation shortly after convalescence from COVID-19 with subsequent partial seroreversion as well as recurrence and prolonged shedding of viral RNA.

Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients


Authors: Canziani, Lorenzo M.; Trovati, Serena; Brunetta, Enrico; Testa, Amidio; De Santis, Maria; Bombardieri, Emilio; Guidelli, Giacomo; Albano, Giovanni; Folci, Marco; Squadroni, Michela; Beretta, Giordano D.; Ciccarelli, Michele; Castoldi, Massimo; Lleo, Ana; Aghemo, Alessio; Vernile, Laura; Malesci, Alberto; Omodei, Paolo; Angelini, Claudio; Badalamenti, Salvatore; Cecconi, Maurizio; Cremonesi, Alberto; Selmi, Carlo

In cases of COVID-19 acute respiratory distress syndrome, an excessive host inflammatory response has been reported, with elevated serum interleukin-6 levels. In this multicenter retrospective cohort study we included adult patients with COVID-19, need of respiratory support, and elevated C-reactive protein who received intravenous tocilizumab in addition to standard of care. Control patients not receiving tocilizumab were matched for sex, age and respiratory support. We selected survival as the primary endpoint, along with need for invasive ventilation, thrombosis, hemorrhage, and infections as secondary endpoints at 30 days. We included 64 patients with COVID-19 in the tocilizumab group and 64 matched controls. At baseline the tocilizumab group had longer symptom duration (13 +/- 5 vs. 9 +/- 5 days) and received hydroxychloroquine more often than controls (100% vs. 81%). The mortality rate was similar between groups (27% with tocilizumab vs. 38%) and at multivariable analysis risk of death was not significantly influenced by tocilizumab (hazard ratio 0.61, 95% confidence interval 0.33-1.15), while being associated with the use at baseline of non invasive mechanical or invasive ventilation, and the presence of comorbidities. Among secondary outcomes, tocilizumab was associated with a lower probability of requiring invasive ventilation (hazard ratio 0.36, 95% confidence interval 0.16-0.83; P = 0.017) but not with the risk of thrombosis, bleeding, or infections. The use of intravenous tocilizumab was not associated with changes in 30-day mortality in patients with COVID-19 severe respiratory impairment. Among the secondary outcomes there was less use of invasive ventilation in the tocilizumab group.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket